Andy Cohen TRT: What a Celebrity Pays vs. A Regular Patient

Andy Cohen and Testosterone Replacement Therapy

Andy Cohen, 56, has mentioned hormone optimization in multiple media appearances, describing improvements in energy, mood, and body composition after starting hormone therapy. He has not published a detailed protocol, but based on his age, stated symptoms before treatment, and the standard of care for men in their mid-50s, a clinically plausible picture emerges. Hypogonadism, defined by the Endocrine Society as a total testosterone below 300 ng/dL confirmed on two separate morning samples, affects an estimated 2.1 to 3.8 million men in the United States [1].

What Likely Qualifies a Man in His 50s

Men between 50 and 59 experience an average testosterone decline of roughly 1 to 2 percent per year after age 30, according to data from the Baltimore Longitudinal Study of Aging [2]. By the mid-50s, a meaningful percentage of men who were previously eugonadal cross the clinical threshold. Symptoms Cohen has referenced publicly, including fatigue and changes in physique, map directly to the symptom cluster the Endocrine Society lists as indications for evaluation: decreased energy, reduced libido, loss of muscle mass, and increased adiposity [1].

Why a Public Figure Gets a Different Entry Point

A concierge physician serving a celebrity client can order same-day lab draws, review results within hours, and prescribe without the multi-week wait that characterizes most primary-care referrals. The clinical decision is identical. The experience is not.

The Standard TRT Protocol: What the Guidelines Actually Say

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends testosterone therapy for men with consistently low serum testosterone and symptoms, with the goal of achieving mid-normal physiologic levels, generally 400 to 700 ng/dL [1]. The guideline states directly: "We suggest against testosterone therapy in men who are planning fertility in the near term." That single contraindication aside, the protocol is well-established.

Injectable Testosterone Cypionate

Testosterone cypionate is the most common formulation in the United States. The standard starting dose is 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days [1]. A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=2,399 across 11 RCTs) found that injectable testosterone consistently raised total testosterone into the normal range and produced statistically significant improvements in sexual function and mood compared with placebo (P<0.001) [3].

Topical Gels and Transdermal Options

Testosterone gel (1.62%, brand name AndroGel) applied daily to the shoulders or upper arms is FDA-approved and avoids injection-site discomfort [4]. Absorption varies by individual, and transfer to partners or children through skin contact is a documented risk the FDA has flagged with a black-box warning [4]. For a celebrity client, a concierge physician may prefer gel or a compounded cream for convenience during travel.

Pellet Implants

Subcutaneous pellet implants (Testopel, 75 mg per pellet) are inserted every 3 to 6 months in a brief in-office procedure. A single insertion session for a typical male patient involves 6 to 12 pellets. This format appeals to high-schedule patients who cannot adhere to weekly injections. Published data show pellets maintain serum testosterone in the 400 to 900 ng/dL range for 4 to 6 months in most patients [5].

The Cost Gap: Celebrity Concierge vs. Regular Patient

The price difference between celebrity-tier TRT and standard-access TRT is not driven by different drugs. Testosterone cypionate costs roughly $30 to $60 for a 10 mL vial (200 mg/mL) at a retail pharmacy, which covers one to two months of injections at standard doses. The gap is driven by access, monitoring frequency, and physician availability.

What a Celebrity Likely Pays

A concierge internal medicine or men's health physician in New York or Los Angeles charges an annual membership fee of $5,000 to $30,000, which covers unlimited visits, same-day labs, and 24/7 physician access. TRT management sits within that membership. On top of that, compounded testosterone creams or specialty lab panels (including free testosterone by equilibrium dialysis, SHBG, sensitive estradiol) can add $200 to $500 per quarter. All-in, the effective monthly cost for celebrity-tier TRT runs $300 to $800, most of it paying for access rather than molecules.

What a Regular Patient Pays Through Telehealth

Telehealth-based men's health platforms now deliver a medically supervised TRT protocol for $99 to $199 per month, which typically includes an async or synchronous physician consultation, a home lab kit or discounted lab order, and the medication shipped directly. A 2022 JAMA Internal Medicine analysis noted that direct-to-consumer testosterone prescribing via telehealth increased 617 percent between 2016 and 2020, raising both access and quality-control questions [6]. The clinical protocol at a reputable telehealth provider follows the same Endocrine Society thresholds a concierge doctor uses.

Insurance Coverage for TRT

Traditional insurance covers FDA-approved testosterone formulations when the patient carries a confirmed hypogonadism diagnosis (ICD-10 E29.1). Out-of-pocket costs with insurance average $20 to $50 per month for testosterone cypionate generic after the copay. The barrier is not the drug cost. It is the diagnostic pathway: a primary care referral, an endocrinology consult, and two separate morning blood draws often span 6 to 12 weeks in a standard health system.

The table below summarizes the three access tiers:

| Access Tier | Monthly Cost | Time to First Prescription | Monitoring | |---|---|---|---| | Celebrity concierge | $300, $800 | Same day to 48 hours | Quarterly labs, 24/7 physician | | Telehealth direct-to-consumer | $99, $199 | 3 to 7 days | Labs every 3 to 6 months, async MD | | Insurance/primary care | $20, $50 (drug only) | 6 to 12 weeks | Annual labs, PCP |

Monitoring: What Gets Tracked and How Often

Both the Endocrine Society guideline and the American Urological Association recommend follow-up labs at 3 and 6 months after initiating TRT, then annually thereafter [1][7]. The panel includes total testosterone (target 400 to 700 ng/dL), hematocrit (flag if above 54%), PSA (relevant for men over 40), and estradiol (sensitive assay, target 20 to 40 pg/mL).

Hematocrit and Polycythemia Risk

Testosterone stimulates erythropoiesis. A hematocrit above 54% increases blood viscosity and raises the risk of thrombotic events. The Endocrine Society recommends holding or dose-reducing TRT if hematocrit exceeds this threshold [1]. In clinical practice, dose reduction from 200 mg to 100 mg weekly, or switching from every-14-day to every-7-day injections to smooth peaks, resolves most cases of mild erythrocytosis.

Estradiol Management

Testosterone aromatizes to estradiol. Elevated estradiol (above 40 to 50 pg/mL on a sensitive assay) can cause gynecomastia, water retention, and mood changes. Some protocols include anastrozole 0.25 to 0.5 mg twice weekly as an aromatase inhibitor, though the Endocrine Society notes the evidence base for routine AI use in TRT is weak, and most men do not need it [1]. Concierge physicians tend to use AIs more liberally than guideline-only practitioners.

Fertility and HCG

Exogenous testosterone suppresses LH and FSH, halting testicular testosterone production and spermatogenesis. Men who want to preserve fertility use human chorionic gonadotropin (hCG) 500 to 1,000 IU two to three times per week alongside TRT to maintain intratesticular testosterone and sperm production [1]. A 2013 study in Fertility and Sterility (N=49) confirmed that co-administration of hCG with testosterone maintained sperm concentrations above 10 million/mL in 89.8% of participants [8].

Body Composition and Performance: What TRT Realistically Delivers

Television personalities in demanding production schedules have a professional interest in maintaining the appearance benefits TRT can provide. The clinical data are specific about magnitude. A 2016 NEJM Testosterone Trials study (N=790 men, mean age 72) found that testosterone treatment produced a mean increase of 1.9 kg in lean mass and a mean decrease of 1.4 kg in fat mass over 12 months compared with placebo [9]. Younger men with more severe deficiency tend to see larger changes.

What Changes and When

Energy and libido typically improve within 3 to 6 weeks of reaching therapeutic testosterone levels. Mood stabilization follows a similar timeline. Changes in lean body mass and fat distribution require 3 to 6 months of consistent treatment and do not substitute for resistance training and caloric management. Bone mineral density, a longer-term benefit, takes 12 to 24 months to show measurable improvement on DEXA [1].

What TRT Does Not Do

TRT does not produce the physique of a pharmacological user taking supraphysiologic doses. Replacing deficient testosterone to mid-normal physiologic levels does not increase muscle mass beyond what that individual's genetics and training support at normal hormone levels. The Testosterone Trials authors noted that the magnitude of lean mass gain was "modest" and that "the clinical significance for individual patients remains to be determined" [9].

Risks and Contraindications

TRT carries documented risks that apply equally to celebrity patients and everyone else. The FDA label for testosterone products carries warnings for cardiovascular risk, sleep apnea exacerbation, and venous thromboembolism [4]. A 2014 PLOS ONE study (N=55,593) found a 30% increase in myocardial infarction risk in men over 65 and a nearly 2-fold increase in men under 65 with pre-existing heart disease in the 90 days after initiating TRT [10]. Subsequent large randomized trials have produced more reassuring data, but the debate is not fully settled.

Absolute Contraindications

The Endocrine Society lists breast cancer, prostate cancer, a palpable prostate nodule without evaluation, hematocrit above 54%, untreated severe obstructive sleep apnea, and severe lower urinary tract symptoms as contraindications or reasons to defer treatment [1]. PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk men) warrants urology referral before initiating TRT.

Cardiovascular Monitoring

The 2023 TRAVERSE trial (N=5,246 hypogonadal men with or at high risk for cardiovascular disease) found that testosterone replacement did not increase the rate of major adverse cardiovascular events compared with placebo over a mean follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [11]. The trial also found a higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm, underscoring the need for individualized risk assessment.

The Telehealth Access Question

The rapid growth of direct-to-consumer TRT platforms has improved access for men who previously could not manage the specialist referral system. The same JAMA Internal Medicine analysis that documented the 617% telehealth TRT prescribing increase also raised concerns that some platforms were prescribing without confirmatory lab documentation [6]. A reputable telehealth TRT provider requires two fasting morning testosterone draws, a symptom questionnaire, and a baseline PSA before prescribing. Patients should verify that their provider follows Endocrine Society diagnostic criteria before accepting a prescription.

The Endocrine Society guideline is explicit: "We recommend against universal screening of all men for androgen deficiency and suggest making the diagnosis only in men with symptoms and signs consistent with androgen deficiency and unequivocally low serum testosterone concentrations" [1].